Mortality risks associated with sibling heart failure
The mortality in individuals with a family history of heart failure (HF) has not been determined. This nationwide sib-pair study aimed to determine mortality in individuals with a sibling affected with HF.
AbstractOver the recent years, studies have emerged reporting on a strong relationship between the occurrence of malignancy and Takotsubo syndrome. The aim of this systematic review and meta-analysis is to evaluate the predictive value of malignancy for prognosis of Takotsubo syndrome patients. PubMed, EMBASE, Cochrane Library, Web of science, and Scopus were searched until 4 September 2019 for articles concerning association of malignancy with the prognosis of Takotsubo syndrome. A total of ten studies were finally included in this meta-analysis, demonstrating that malignancy was associated with higher mortality in Takots...
Conclusion: The presence of clinically significant TR is associated with an increase in healthcare utilization and expenditures, irrespective of the presence of HF. PMID: 31952454 [PubMed - as supplied by publisher]
Patients with heart failure with reduced ejection fraction (HFrEF) can be treated with mineralocorticoid receptor antagonists (MRAs) and are unlikely to develop hypotension as a result, an analysis of two large randomized trials reveals.Reuters Health Information
We read with interest the article by Couselo-Seijas et al. “High released lactate by epicardial fat from coronary artery disease patients is reduced by dapagliflozin treatment” . The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors (SGLT-2i) is gradually increasing in diabetes mellitus (DM) and heart failure treatment. Increasing pieces of n ovel information are added to the literature on these drugs. We strongly agree with the authors' findings. The article has led us to consider lactate levels in euglycemic (E) diabetic ketoacidosis (DKA) due to SGLT2i use, and the usefulness of metformin and SGLT-2i combination.
Conclusion: The efficacy and additional benefits of FZF for CCEs were certain according to the high-quality evidence assessed through GRADE. However, the efficacy and additional benefits for the other outcomes were uncertain judging from current studies. In addition, the safety assessment has a great room for improvement. Thus, further research studies are needed to find more convincing proofs. PMID: 31949473 [PubMed]
ConclusionsThis study demonstrated a vital role of calpain in ECs for inducing myocardiocyte hypertrophy, cell death and the EndMT via the HSP90/Akt signaling pathway, thereby promoting cardiac fibrosis. The results indicate that inhibiting ECs calpain is a novel therapeutic target to retard cardiac fibrosis and has positive effects on heart failure.Graphical abstract
This study adds to the body of evidence in describing incidence and type of cardiac events experienced by an allogeneic and autologous HSCT population at one institution from 2012-2017. Sixty-five patients (9.8%) experienced cardiac events, including atrial arrhythmia (N = 39), acute heart failure (N = 9), acute coronary syndrome (N = 7), new onset hypertension (N = 9), with a few instances of bradycardia, ventricular arrhythmia, pericardial effusion, and pericarditis. Our multivariable regression analysis identified age (older), creatinine (higher) and history of coronary artery disease to significantly correlate with ris...
No abstract available
Publication date: Available online 17 January 2020Source: PhytomedicineAuthor(s): Rui Guo, Ningning Liu, Hao Liu, Junhua Zhang, Han Zhang, Yingchao Wang, Mirko Baruscotti, Lu Zhao, Yi WangAbstractBackground: Cardiac hypertrophy is a prominent feature of heart remodeling, which may eventually lead to heart failure. Tongmaiyangxin (TMYX) pills is a clinically used botanical drug for treating multiple cardiovascular diseases including chronic heart failure. The aim of the current study was to identify the bioactive compounds in Tongmaiyangxin pills that attenuate cardiomyocytes hypertrophy, and to investigate the underlying m...
Acute cardiogenic pulmonary oedema (ACPO) is one of the common causes of acute respiratory failure, constituting 10% –20% of acute heart failure syndromes and potentially causing death . Acute cardiogenic pulmonary oedema ACPO usually presents with sudden dyspnoea at rest, impaired exertion capacity, tachypnoea, tachycardia and hypoxia. Increased endogenous catecholamine levels and hypertension due to stress are common in cases with good left ventricular function. Cough is a frequent finding in these cases.